Docetaxel plus cyclophosphamide is cost-effective compared to doxorubicin plus cyclophosphamide, based on an economic analysis of US oncology trial 9735: additional rationale to avoid anthracyclines in the adjuvant treatment of operable breast cancer?

被引：0
|
作者：
Verma, S.
Mittmann, N.
Bernard, L.
Thompson, M.
Chan, B.
Asmar, L.
Jones, S.
机构：
[1] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[2] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[3] Cornerstone Res Grp Inc, Burlington, ON, Canada
[4] US Oncol Res, Houston, TX USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：378S / 378S
页数：1
相关论文
共 42 条
  • [21] Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines
    Trudeau, Maureen E.
    Clemons, Mark J.
    Provencher, Louise
    Panasci, Lawrence
    Yelle, Louise
    Rayson, Daniel
    Latreille, Jean
    Vandenberg, Ted
    Goel, Rakesh
    Zibdawi, Labib
    Rahim, Yasmin
    Pouliot, Jean-Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) : 5906 - 5910
  • [22] Predictive factors of anthracycline or taxan based chemotherapy: Analysis from a randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer
    Ishikawa, Takashi
    Narui, Kazutaka
    Shimada, Kazuhiro
    Kida, Kumiko
    Sugae, Sadatoshi
    Ichikawa, Yasushi
    Tanabe, Mikiko
    Endo, Itaru
    Oba, Mari S.
    CANCER RESEARCH, 2014, 74 (19)
  • [23] Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
    Katsumata, N.
    Watanabe, T.
    Minami, H.
    Aogi, K.
    Tabei, T.
    Sano, M.
    Masuda, N.
    Andoh, J.
    Ikeda, T.
    Shibata, T.
    Takashima, S.
    ANNALS OF ONCOLOGY, 2009, 20 (07) : 1210 - 1215
  • [24] Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
    Perez, EA
    Suman, VJ
    Davidson, NE
    Kaufman, PA
    Martino, S
    Dakhil, SR
    Ingle, JN
    Rodeheffer, RJ
    Gersh, BJ
    Jaffe, AS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) : 3700 - 3704
  • [25] Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer
    Martin, M.
    Mackey, J.
    Pienkowski, T.
    Rolski, J.
    Guastalla, J-P
    Sami, A.
    Glaspy, J.
    Juhos, E.
    Wardley, A.
    Fornander, T.
    Hainsworth, J.
    Coleman, R.
    Modiano, M.
    Vinholes, J.
    Pinter, T.
    Childs, B.
    Roessner, M.
    Wilson, V.
    Rupin, M.
    Vogel, C.
    CANCER RESEARCH, 2010, 70
  • [26] A phase III, randomized trial of docetaxel plus carboplatin (TP) versus epirubicin plus cyclophosphamide followed by docetaxel (EC-T) as adjuvant treatment for triple-negative, early-stage breast cancer in Chinese patients.
    Yuan, Peng
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] First safety data from a randomised phase III trial comparing adjuvant epirubicin-cyclophosphamide → docetaxel (EC → T) vs ET capecitabine (X) in N plus operable breast cancer (BC)
    Martin, M.
    Lluch, A.
    Ruiz-Simon, A.
    Ribelles, N.
    Ruiz-Borrego, M.
    Rodriguez-Lescure, A.
    Munoz, M.
    Ramos, M.
    Gonzalez, S.
    Margeli, M.
    BREAST, 2009, 18 : S55 - S55
  • [28] Sequential treatment of docetaxel plus doxorubicin/cyclophosphamide (AC) as first-line chemotherapy for metastatic breast cancer (MBC).: Final results and survival analysis of a phase II study
    Antón, A
    Colomer, R
    Lluch, A
    Massuti, B
    Corral, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S69
  • [29] Cost-effectiveness of adjuvant chemotherapy for node plus breast cancer: modeling the downstream effects of adjuvant TAC vs FAC: docetaxel (T), adriamycin (A), cyclophosphamide (C) compared to 5-fluorouracil (F) A C.
    Au, HJ
    Golmohammadi, K
    Chia, S
    Verma, S
    Younis, T
    Chin, C
    Jacobs, P
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S218 - S218
  • [30] NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer
    Swain, Sandra M.
    Tang, Gong
    Geyer, Charles E.
    Rastogi, Priya
    Atkins, James Norman
    Donnellan, Paul P.
    Fehrenbacher, Louis
    Azar, Catherine A.
    Robidoux, Andre
    Polikoff, Jonathan
    Brufsky, Adam
    Biggs, David D.
    Levine, Edward A.
    Zapas, John L.
    Provencher, Louise
    Perez, Edith A.
    Paik, Soonmyung
    Costantino, Joseph P.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345